BioCentury
ARTICLE | Clinical News

Synta falls on ganetespib data

June 4, 2013 2:56 AM UTC

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) fell $2.51 (34%) to $4.87 on Monday after reporting median overall survival (OS) data from an interim analysis of the open-label Phase IIb portion of the international Phase IIb/III GALAXY-1 trial evaluating ganetespib plus docetaxel as second-line treatment to treat advanced, metastatic non-small cell lung cancer (NSCLC). In 252 patients with stage IIIB/IV NSCLC adenocarcinoma, ganetespib plus docetaxel led to a median OS, a secondary endpoint, of 9.8 vs. 7.4 months in patients receiving docetaxel alone (p=0.082). In a subgroup of 176 patients who were enrolled in the trial more than six months after diagnosis of advanced NSCLC, ganetespib plus docetaxel led to a median OS of 10.7 months vs. 6.4 months for docetaxel alone (p=0.0093). Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...